These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 1486391)

  • 1. Phase II study of epirubicin in advanced hormone-resistant prostatic carcinoma.
    Delaere KP; Leliefeld H; Peulen F; Stapper EW; Smeets J; Wils J
    Br J Urol; 1992 Dec; 70(6):641-2. PubMed ID: 1486391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of orchiectomy combined with epirubicin as first-line treatment in advanced prostate carcinoma.
    Leliefeld H; Wils J; Peulen G; Smeets J
    Cancer Invest; 1994; 12(4):395-8. PubMed ID: 8032959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group.
    Brausi M; Jones WG; Fosså SD; de Mulder PH; Droz JP; Lentz MA; van Glabbeke M; Pawinski A
    Eur J Cancer; 1995 Sep; 31A(10):1622-6. PubMed ID: 7488412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of epirubicin for hormone-resistant prostatic cancer with measurable soft tissue disease.
    Tannock IF; Erwin TJ; Stewart DJ; Fontaine B; Gupta S
    Am J Clin Oncol; 1993 Apr; 16(2):156-8. PubMed ID: 8452110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.
    Carmo-Pereira J; Costa FO; Miles DW; Henriques E; Richards MA; Rubens RD
    Cancer Chemother Pharmacol; 1991; 27(5):394-6. PubMed ID: 1999000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma.
    Falcone A; Antonuzzo A; Danesi R; Allegrini G; Monica L; Pfanner E; Masi G; Ricci S; Del Tacca M; Conte P
    Cancer; 1999 Aug; 86(3):470-6. PubMed ID: 10430255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group.
    Di Leo A; Bajetta E; Buzzoni R; Bochicchio AM; Nolè F; Biganzoli L; D'Aprile M; Veltri E; Comella G; Aitini E
    Am J Clin Oncol; 1995 Jun; 18(3):239-44. PubMed ID: 7538260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments.
    Elomaa I; Kellokumpu-Lehtinen P; Rannikko S; Alfthan O
    Eur Urol; 1991; 19(1):12-5. PubMed ID: 1706666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weekly chemotherapy in advanced prostatic cancer.
    Francini G; Petrioli R; Manganelli A; Cintorino M; Marsili S; Aquino A; Mondillo S
    Br J Cancer; 1993 Jun; 67(6):1430-6. PubMed ID: 8512828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of epirubicin in advanced transitional cell bladder cancer. The Yorkshire Urological Cancer Research Group.
    Jones WG; Sokal MP; Ostrowski MJ; Newling DW
    Clin Oncol (R Coll Radiol); 1993; 5(1):25-9. PubMed ID: 8424911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective randomized trial comparing epirubicin monochemotherapy to two fluorouracil, cyclophosphamide, and epirubicin regimens differing in epirubicin dose in advanced breast cancer patients. The French Epirubicin Study Group.
    J Clin Oncol; 1991 Feb; 9(2):305-12. PubMed ID: 1988577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of epirubicin in advanced soft tissue sarcoma.
    Chevallier B; Montcuquet P; Fachini T; Nguyen Bui B; Kerbrat P; Bastit P; Vo Van ML
    Bull Cancer; 1990; 77(10):991-5. PubMed ID: 2249019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly epidoxorubicin therapy in hormone-refractory metastatic prostate cancer.
    Neri B; Barbagli G; Bellesi P; Di Loro R; Lombardi V; Lombardo C; Magrini T; Mottola A; Nicita G; Palminteri E; Ponchietti R; Raugei A; Intini C
    Anticancer Res; 1997; 17(5B):3817-20. PubMed ID: 9427786
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weekly epirubicin in patients with hormone-resistant prostate cancer.
    Petrioli R; Fiaschi AI; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Manganelli A; Salvestrini F; Francini G
    Br J Cancer; 2002 Sep; 87(7):720-5. PubMed ID: 12232753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K; Lehnert M; Stettner H; Hubmer G
    Eur Urol; 1997; 32 Suppl 3():81-5. PubMed ID: 9267791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequentially alternating hormone chemotherapy with high-dose medroxy-progesterone acetate and low-dose epirubicin for the treatment of hormone-resistant metastatic prostatic cancer.
    Kontturi M; Sotarauta M; Tammela T; Lukkarinen O; Romppainen ML; Gröhn P
    Eur Urol; 1988; 15(1-2):43-7. PubMed ID: 2975221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epirubicin high-dose therapy in advanced breast cancer: preliminary clinical data. Epirubicin as a single agent in breast cancer.
    Neri B; Pacini P; Bartalucci S; Moroni F; Menchi I; Cappellini M
    Int J Clin Pharmacol Ther Toxicol; 1989 Aug; 27(8):388-91. PubMed ID: 2793274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomised phase II study of epirubicin-vindesine versus mitoxantrone-vindesine in metastatic breast cancer.
    Hausmaninger H; Lehnert M; Steger G; Sevelda P; Tschurtschenthaler G; Hehenwarter W; Fridrik M; Samonigg H; Schiller L; Manfreda D
    Eur J Cancer; 1995 Dec; 31A(13-14):2169-73. PubMed ID: 8652237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of high-dose epirubicin in advanced non-small cell lung cancer.
    Martoni A; Melotti B; Guaraldi M; Pannuti F
    Eur J Cancer; 1991; 27(10):1231-4. PubMed ID: 1659841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.